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ABSTRACT: The acetylglucosaminyltransferase-like protein LARGE1 is an enzyme that
is responsible for the final steps of the post-translational modifications of dystroglycan
(DG), a membrane receptor that links the cytoskeleton with the extracellular matrix in the
skeletal muscle and in a variety of other tissues. LARGE1 acts by adding the repeating
disaccharide unit [-3Xyl-α1,3GlcAβ1-] to the extracellular portion of the DG complex (α-
DG); defects in the LARGE1 gene result in an aberrant glycosylation of α-DG and
consequent impairment of its binding to laminin, eventually affecting the connection
between the cell and the extracellular environment. In the skeletal muscle, this leads to degeneration of the muscular tissue and
muscular dystrophy. So far, a few missense mutations have been identified within the LARGE1 protein and linked to congenital
muscular dystrophy, and because no structural information is available on this enzyme, our understanding of the molecular
mechanisms underlying these pathologies is still very limited. Here, we generated a 3D model structure of the two catalytic domains
of LARGE1, combining different molecular modeling approaches. Furthermore, by using molecular dynamics simulations, we
analyzed the effect on the structure and stability of the first catalytic domain of the pathological missense mutation S331F that gives
rise to a severe form of muscle−eye−brain disease.
■ INTRODUCTION
Glycosylation is one of the most common post-translational
modifications of proteins in the cell and plays a key role in
physiological and pathological cellular functions.1−3 Glyco-
sylation patterns are altered in a number of diseases including
cancer and neurodegenerative and autoimmune disorders.4
Dystroglycan (DG) is a highly glycosylated membrane
receptor, formed by the two subunits α- and β-dystroglycan
(hereinafter α-DG and β-DG), that connects the extracellular
matrix with the cytoskeleton in many tissues, such as muscle
and brain.5 α-DG is a peripheral membrane protein formed by
two globular domains, the N- and C-terminal domains,
separated by an elongated mucin-like region.6 α-DG binds to
a set of extracellular matrix molecules that harbor one or more
laminin globular domains (LG-domains),7 such as laminin,8
agrin,9 perlecan,10 pikachurin,11 neurexin,12 and slit.13 The
binding properties of α-DG depend on a complex O-mannosyl
glycosylation, a multi-step process that involves at least 17
different enzymes.14 Mutations in any of these enzymes are
linked to a number of muscular dystrophies, collectively known
as secondary dystroglycanopathies, whose clinical presenta-
tions can vary from severe congenital muscular dystrophies to
milder limb-girdle muscular dystrophy with manifestation in
adulthood.15 The hallmark of secondary dystroglycanopathies
is the absence or the significant reduction of α-DG
glycosylation.16 The α-DG O-mannosyl modification starts
with the attachment of a trisaccharide molecule GalNAc-β3-
GlcNAc-β4-Man to Ser/Thr residues in the α-DG mucin-like
region.17 The mannose is then phosphorylated by POMK to
allow further glycan elongation and phosphorylation by
enzymes including fukutin, FKRP, TMEM5, B4GAT1, and
LARGE1.18−21 In particular, LARGE1 is a type II trans-
membrane protein, localized in the Golgi apparatus,22
characterized by two distinct domains, that can be found
within the Golgi lumen, with glycosyltransferase activities: a
xylosyltransferase activity (domain 1) and a glucuronyltransfer-
ase activity (domain 2)18 (Figure 1).
Indeed, LARGE1 catalyzes the addition to its substrate of
several units of the disaccharide [-3Xyl-α1,3GlcAβ1-], known
as matriglycan, which is the functional motif that ensures the
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Figure 1. Schematic representation of LARGE1 domains.
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binding of α-DG to the extracellular matrix proteins.14,23
During DG maturation, LARGE1 binds to the N-terminal
domain of α-DG, and this binding is an essential anchor for the
enzyme to specifically modify the mucin-like region.19,24
Different mutations in LARGE1 have been identified in
patients affected by severe congenital muscular dystrophy with
central nervous system involvement.25−29 These mutations
include missense and frameshift mutations in both domain 1
and domain 2, as well as intragenic deletions/insertions.
Overexpression of LARGE1 in cells from patients affected by
different α-dystroglycanopathies restored α-DG laminin bind-
ing, indicating that the modulation of LARGE1 activity may
represent a therapeutic strategy for the treatment of secondary
dystroglycanopathies.30,31
In this context, the effort to reach a fundamental
understanding of the molecular details of the glycosylation
process is undermined by the lack of high-resolution structural
data on LARGE1. In order to start filling this gap, molecular
modelling can be used to construct a working three-
dimensional model structure of the α-DG glycosylating
enzyme. When structural homologs are not available, as in
the case of LARGE1, ab initio modelling may guide a
conformational search based on a designed energy function,
but, in spite of recent advances, such an approach has shown
low accuracy in prediction.32 Traditional physics-based
potentials for molecular mechanics and conformational
searches, first used for organic compounds,33,34 have not yet
been developed to a point where reliable model structures can
be generated except for a limited number of proteins.32
Knowledge-based energy functions were demonstrated to
perform better,35 and among them, the TASSER approach
ranked as the top method for automated protein structure
prediction in the latest CASP experiments for three-dimen-
sional structure prediction.36,37 TASSER and its development,
I-TASSER gateway, which involves template threading,
structural fragment assembly, model refinement, and struc-
ture-based protein function annotation, indicate that ab initio
and template-based modelling may successfully combine.38 To
date, the only in silico analysis of LARGE1, confined to the
study of LARGE1 domain 2, is that of Bhattacharya et al.39
In this study, we present a three-dimensional model for both
domain 1 and 2 of LARGE1 and analyze their structural
features using the best performing methods for fold
recognition and domain boundary prediction.40,41 The
generated three-dimensional structures were refined, and the
best reliable models were selected and subjected to molecular
dynamics (MD) simulations. MD calculations are useful tools
for evaluating the stability of predicted domains as well as the
effect of a pathological mutation,42−44 and we employed them
in order to provide insight into the outcome of the S331F
mutation found in a patient affected by congenital muscular
dystrophy with eye and brain involvement.26
■ MATERIALS AND METHODS
Functional Domains Prediction and Models Building.
The 756 amino acid long sequence of LARGE1 from Mus
musculus was retrieved from the UniProt database (http://
www.uniprot.org/)45 (entry code Q9Z1M7), and the domain
analysis was performed using the Conserved Domain Database
(CDD) server.46 Following a successful modelling strategy,47
two different protein-modelling approaches were employed to
build the molecular models of the identified LARGE1 protein
domains: HHPRED48 in combination with MODELLER49
and the I-TASSER server.50 The web-service HHpred,
available at https://toolkit.tuebingen.mpg.de/tools/hhpred,
offers a threading approach that uses the hidden Markov
models51 and was employed to align the sequences and search
for suitable template structures. The PDB70 profile database
was used for the template search, and the crystallographic
structure showing the best HHpred probability score, the
largest coverage, and the best resolution was chosen as a
template. The resulting alignment was submitted to the
program MODELLER v 9.15 as implemented in Discovery
Studio 2016 (Dassault System̀es BIOVIA, Discovery Studio
Modelling Environment, Release 2016, San Diego: Dassault
System̀es, 2016) to build the three-dimensional structure of
the identified LARGE1 domains. Fifty models with a degree of
optimization scored as “high” were generated by the “Build
Homology Model” protocol of Discovery Studio and ranked by
the PDF total energy. The best-ranked models were then
submitted to the “Loop Refinement” protocol of the program
generating five models for each loop, with a “high”
optimization level. The refined models with the lowest PDF
total energy score were chosen as the final models. For
comparison, the I-TASSER web-service was also used, a meta-
server that automatically employs ten threading algorithms in
combination with ab initio modelling to build the tertiary
structure of a protein as well as replica-exchange Monte Carlo
dynamics (REMD) simulations for the atomic-level refine-
ment. PROCHECK52 and ProSA-Web53 were employed to
evaluate the quality of the model. The structure of the mutant
S331F of LARGE1 domain 1 was carried out with the “Build
Mutant” protocol of the BIOVIA Discovery Studio suite
(Dassault System̀es BIOVIA, Discovery Studio Modelling
Environment, Release 2016, San Diego: Dassault System̀es,
2016). Fifty models were generated with a “high” optimization
level and with no restraints and evaluated based on their PDF
total energy and DOPE score.
Molecular Dynamics Simulations of WT and of the
S331F Mutant. Molecular dynamics simulations were
executed using the version 4.8 of Desmond (D. E. Shaw
Research, New York) employing the OPLS2005 force field.54
An all-hydrogen model of the proteins was first generated using
the Protein Preparation Wizard tool55 available in the Maestro
software (Schrödinger, LLC, New York, NY, 2017), for
hydrogen insertion and force field atom-types and partial
charges assignment. The systems for the simulations were built
with the “System Builder” tool of the Maestro suite, drawing a
triclinic box around the domain 1 of LARGE1 with a distance
buffer of 10 Å between the protein and the side of the box, and
filling it with SPC water molecules. A 0.15 mol/L NaCl salt
concentration was added, and additional Cl− ions were added
to neutralize the system (Table 1). The resulting systems both
consisted of a 71 × 76 × 71 Å-sized box containing a total of
about 30000 atoms, among which ∼8800 were water
molecules and ∼4590 were protein atoms (Table 1).
The two systems were first minimized in order to relax the
molecules into a local energy minimum and to remove the
steric clashes, using the default protocol consisting of an initial
steepest descent phase followed by a minimization with the
LBFGS method, until convergence. The systems were then
equilibrated using the Desmond standard NPT relaxation
protocol with default parameters. We performed duplicate MD
simulations of 500 ns each, using different random seeds for
the assignment of the initial velocities, at a constant pressure of
1 atm and 300 K, saving the energies and the trajectories every
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20 ps. The Martyna−Tobias−Klein method was used for
pressure coupling, and the Nose−Hoover thermostat was
employed for the temperature bath, using the default settings
for both, while a cut-off of 9 Å was used for the non-bond
interactions. The analysis of trajectories was performed with
the “simulation event analysis” tool of Maestro (Maestro-
Desmond Interoperability Tools, Schrödinger, New York, NY,
2017), and the solvent accessible surface area (SASA) over the
simulation time was calculated with VMD.56 Discovery Studio
(Dassault System̀es BIOVIA, Discovery Studio, 2018, San
Diego: Dassault System̀es, 2018), Maestro, and VMD were
used for the visual inspection of the three-dimensional
structures and for the simulations results. The convergence
of the MD simulations was assessed by calculating the root
mean square inner product (RMSIP) using Bio3D library as
implemented in the version 3.5.2 of the R package.57,58
The protein motion essential for the biological function of
LARGE1 was analyzed by principal component analysis
(PCA)-based dimensionality reduction of the atomic fluctua-
tions of the Cα atoms in the simulated trajectory. The Bio3D
library,58 as implemented in the version 3.5.2 of the R package,
was employed to perform and graphically represent the PCA of
the WT and the S331F mutant trajectories. The conformations
from the last 210 ns replica MD simulations were used for the
wild-type (WT) and mutant enzymes. All the calculations were
carried out employing an NVIDIA M4000 GPU and an Intel
Xeon X5660 processor, on a HPZ820 workstation running
Linux Centos 7 operating system. FoldX v5.0 was used to
estimate the impact of the S331F mutation on protein stability
(http://foldxsuite.crg.eu).59 The algorithm calculates the free
energy of folding of the WT and the mutated protein and
estimates whether the mutation has a destabilizing (ΔΔG > 0)
or stabilizing (ΔΔG < 0) effect.
Cloning and Expression of LARGE1 Domain 1 in
Escherichia coli. The nucleotide sequence of LARGE1
domain 1 (residues 138−413) from M. musculus was
synthesized and optimized for expression in E. coli by
Invitrogen (GeneArt gene synthesis). The synthetic gene was
cloned with extremities 5′BamHI-3′EcoRI downstream the
thioredoxin gene in the vector pHisTrx, for expression in E. coli
as a fusion product; the expression vector thus obtained was
transformed into E. coli BL21 (DE3). A single colony from the
transformants was picked and grown o.n. in LB + Amp 100
mg/L, then diluted 100-fold in fresh LB + Amp 100 mg/mL,
and grown at 30 °C shaking at 220 rpm until OD600 ≈ 0.8;
the expression was induced by adding IPTG to 0.5 mM final
concentration. Protein production was checked on single
aliquots collected at specific times after induction by lysing the
cell pellets and running them on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). The bulk of
cells was collected 3 h after induction, and the cell pellet was
resuspended and lysed; the soluble proteins were separated
from the insoluble ones by high-speed centrifugation and
finally checked on SDS-PAGE in order to identify which
fraction contained the fusion product. To increase the
solubility of LARGE1 domain 1, the same construct was
used to transform Arctic Xpress E. coli BL21 (DE3) competent
cells (Agilent Technologies) following the manufacturer
instructions. A single colony from the transformants was
picked and grown o.n. in LB containing ampicillin 100 mg/L
and gentamicin 20 mg/L, then diluted 200× in fresh LB
containing no selection antibiotic, and grown at 30 °C shaking
at 220 rpm for 3 h. The expression was then induced by adding
IPTG to 1 mM final concentration and growing the cells for
additional 24 h at 12 °C shaking at 200 rpm. Cells were
harvested, resuspended in binding buffer (20 mM Tris HCl,
0.5 M NaCl, 15 mM imidazole, 2 mM Mn2+), and lysed in a
cell disruptor (Constant Systems, model Z plus 1.1 KW). The
soluble and insoluble fractions were separated by centrifuga-
tion, and the supernatant was loaded on a 5 mL His trap Ni2+
column equilibrated in binding buffer, for isolation of the His-
tagged fusion product by binding and imidazole elution.
Table 1. Details of the Starting Structures for MD
Simulations
system property WT S331F mutant
number of atoms 30,017 30,963
protein residues 276 276
protein atoms 4585 4594
water molecules 8773 8752
Cl− ions 31 31
Na+ ions 24 24
Mn2+ ion 1 1
size (Å) 71.2 × 66.4 × 70.5 71.2 × 66.4 × 70.5
ligand atoms 55 55
protein charge +7 +7
ligand charge −2 −2
Figure 2. Schematic of the methodology employed for modelling LARGE1 domains 1 and 2.
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Expression and purification outcomes were checked on SDS-
PAGE.
■ RESULTS AND DISCUSSION
Molecular Modelling. A schematic summarizing the
workflow of our molecular modelling approach is provided in
Figure 2.
Molecular Modelling of LARGE1 Domain 1. We
decided to use the murine LARGE1 sequence for molecular
modelling due to the very high degree of sequence similarity
between murine and human variants (100% sequence identity
for domain 1 and 98.5 for domain 2, Supporting Information,
Figure S1). It is worth noting that we have recently shown that
the X-ray structures of murine and human N-terminal of α-
dystroglycan (displaying the same degree of sequence
similarity found between human and murine LARGE1) are
identical.60 As for the human point mutation of LARGE1 that
we have introduced and analyzed in the model and in
agreement with the above, all the residues in the region
specifically perturbed by the mutation S331F in murine
LARGE1 are identical to those in its human counterpart.
The xylosyltransferase and glucuronyltransferase activities of
LARGE1 have been attributed to two different domains of the
protein.18 Indeed, the identification of functional domains by
the CDD server revealed the presence of two domains, namely,
domain 1 (residues 138−413) and domain 2 (residues 473−
742), both predicted to belong to two glycosyltransferase
families (family 8 and 49, respectively), in agreement with the
data reported in the literature.18,61 The absence of a suitable
template structure in the Protein Data Bank for homology
modelling of the whole-length protein led us to generate three-
dimensional model structures of the two identified domains
individually. The HHpred analysis on domain 1 (residues
138−413) identified three potential templates in the Protein
Data Bank: the crystal structure of a protein belonging to the
glycosyltransferase family 8 from Anaerococcus prevotii (PDB
code 3TZT62), the crystal structure of the galactosyltransferase
LgtC from Neisseria meningitidis (PDB code 1G9R63), and the
crystal structure of the xyloside xylosyltransferase 1 from M.
musculus (PDB code 4WMA64). Amongst these, 1G9R (2 Å
resolution, 19% sequence identity) was selected as the
template structure because it exhibited the lowest number of
missing residues. The HHpred alignment was then used by
MODELLER for model building. Structural models were
generated, and the highest-scoring model (lowest PDF total
energy) was selected for further analysis. The quality of the
model was evaluated considering the overall stereochemistry
by PROCHECK, and the resulting Ramachandran plot showed
that 95.7% of residues was located in the most favorable
regions (core and allowed), whereas the 3.9% was located
within the generously allowed region and only the 0.4%,
confined to Lys 386, in the disallowed region. The interaction
energy of each residue with the structural surrounding
environment, calculated with PROSA-Web, gave a global Z-
score of −5.6 (276 residues), which falls well within the
accepted range for proteins of the same size and indicates an
overall good model quality (Supporting Information, Figure
S2A). The PROSA-Web local quality analysis of the model,
represented in the energy profile plot, shows that all the
residues, except those in regions 265−285, have negative
scores, where the more negative is the score, the more
correctly modeled is the region (Supporting Information,
Figure S2B).
For comparison, an alternative approach was used and the
model of domain 1 was also generated on the I-TASSER
server, which is based on a combination of multiple-threading
alignments, iterative template fragment assembly simulations,
and ab initio modelling algorithms. The template search stage
of the I-TASSER procedure identified the crystal structures of
the galactosyltransferase LgtC from N. meningitidis (PDB entry
codes: 1G9R,63 1GA8,63 and 1SS965) of a glycosyltransferase
family 8 from A. prevotii (PDB code 3TZT62) and of the
xyloside-α-1,3-xylosyltransferase 1 (XXYLT1) from Homo
sapiens (PDB code 4WM064) as the best templates. In
agreement with the HHpred results, all the templates detected
by I-TASSER displayed the typical GT-A fold, consisting of
two α/β/α domains with a continuous central β-sheet,66 all
belonging to family 8. Identified templates share sequence
identity with the target sequence ranging from 19 to 24%
(Supporting Information, Table S1). Five I-TASSER models
were obtained, and the best scoring model displayed a TM-
score of 0.79 ± 0.09, an estimated root-mean-square deviation
(rmsd) of 4.8 ± 3.1 Å and, on a scale of accuracy ranging from
−5 (lowest) to 2 (highest), a C-score value of 0.57. The model
structure obtained from the I-TASSER procedure featured a
lower percentage of residues (87%) in the core and allowed
regions of the Ramachandran plot and 6.7 and 5.9% residues in
the generously allowed and disallowed regions, respectively.
The ProSA-web local quality analysis of this model reported
negative energy values for all the residues, with the exception
of the region 271−296, and the global quality analysis (276
residues) gave a Z-score of −6.92, which falls within the range
of the experimentally resolved structures of the same size
(Supporting Information, Figure S3A,B). The models
generated by I-TASSER and HHpred were submitted to the
COFACTOR software,67 which identifies the most structurally
similar enzymes in the Protein Data Bank, performing a local
and global structure match. This analysis showed that the two
generated models share the highest structural similarity with
the crystallographic structure of the glycosyltransferase LgtC
from N. meningitidis (PDB code number 1SS9), displaying a
TM-score of 0.89 and 0.92 for the I-TASSER and HHpred
model, respectively, as well as a Cα-rmsd lower than 2 and a
sequence coverage of 94.6% for both the model structures.
Given that a TM-score greater than 0.7 indicates that the
structures have a 90% probability of being in the same
topology family,68 the two models of domain 1 can thus
confidently be assigned to the GT-A glycosyltransferase family.
For comparison, the calculated Cα-rmsd values between the
MODELLER and I-TASSER LARGE1 models are 2.3 Å
(domain 1) and 4.1 Å (domain 2), indicative of similar models.
According to the validation results, the model structure
obtained by the combined HHpred/MODELLER approach
was selected as the best model for LARGE1 domain 1 for
further analysis. The model structure of domain 1 consists of a
central seven-stranded mainly parallel β-sheet (Figure 3A),
sandwiched between 14 α-helices and a small β-sheet, which is
conserved in all the proteins with a GT-A fold (Figure 3A,B).
On one side of the β-sheet, helix-C contacts the β1 and β2
strands, whereas helices G, J, and K contact the rest of the β-
sheet. On the other side, a small β-sheet (strands β5 and β9) is
located between helices A, B, and N that are in contact with
the β1, β2, and β3 strands, whereas helices D, L, M, and E are
in contact with the β6 and β8 strands (Figure 3). As found in
other GT-A folded proteins, the small β-sheet formed by two
antiparallel strands (β5 and β9) is linked to the β4 strand by a
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loop (L4) that contains a conserved DXD motif likely to bind
the manganese cation (Mn2+)69 responsible for the catalytic
activity of domain 1.18,22 The Mn2+ ion has a crucial role in the
catalytic activity of LARGE1, and it is coordinated by the DXD
motif residues as well as by the α- and β-phosphate moieties of
the substrate.63 In the predicted model structure of LARGE1
domain 1, the Mn2+ ion is coordinated by the NE2 atom of
His380 of the β9 strand and by the carboxylate oxygen atoms
of Asp242 and Asp244 belonging to the β4−β5 linker loop L4
(Figure 3B). Analogous interactions are established by the
Mn2+ ion in the neighbor crystallographic structure of LgtC
from N. meningitidis (1G9R) where the cation is coordinated
by His244, Asp103, and Asp105, respectively (ref 63, Figure
4).
Full inspection of the structural alignment reveals that all
major secondary structure elements of the model of LARGE1
domain 1 superimpose almost exactly with those of the LgtC
glycosyl transferase, with only few exceptions related to the
helical content (Figure 4).
Molecular Modelling of LARGE1 Domain 2. An
analogous analysis was performed for LARGE1 domain 2.
The top-ranking templates identified with a 99.7% probability
by the template search methods of HHpred were all N-
acetylgalactosaminyl transferases, namely, 1XHB,70 6E4R,71
6H0B,72 6IWR,73 and 2D7I.74 1XHB, the crystal structure of
the UDP-GalNAc: polypeptide α-N-acetylgalactosaminyltrans-
ferase-T1 from M. musculus, was selected as the best template
because it exhibited the highest P-value (2.0 × 10−19), highest
probability (99.7%), and a sequence identity of 10% with the
target. The stereochemical quality of the model with the lowest
PDF value, generated by MODELLER on the basis of the
HHpred alignment, was evaluated using PROCHECK. The
Ramachandran plot calculation revealed that 91.5% of the
residues are found in the most favorable regions (core and
Figure 3. Structure and topology of LARGE1 domain 1. (A)
Topology diagram of the domains. Helices are shown as red spheres,
and β-strands are shown as yellow triangles. (B) Structural model
represented as a cartoon, and the secondary structure is colored
(helices in red, β-strands in yellow, and random coils in magenta).
Individual side chains are represented in green as balls and sticks.
Figure 4. Structure-based sequence alignment of LARGE1 domain 1 and LgtC from N. meningitidis. Numbering is relative to the sequence of
LARGE1, and the secondary structure elements of LgtC are based on Persson et al.63 The figure was prepared using the ESPript server (http://
espript.ibcp.fr). Identical residues are shown in white on red, and homologous residues are in red letters. Secondary structure details are represented
(helices: squiggles, beta strands: arrows, and turns: TT letters).
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allowed), 3.7% in the generously allowed region, and the
remaining 4.9% in the disallowed region. ProSA-Web analysis
of the model (270 residues) revealed a Z-score value of the
target protein of −2.69, that is, within the range of the
experimental protein structures of the same size, which
indicates an acceptable overall quality of the model structure.
However, the ProSA-Web analysis revealed that about 50% of
the residues display positive values of interaction energy,
suggesting errors in some regions of the model (Supporting
Information, Figure S4A,B). The crystallographic templates
found by I-TASSER to be suitable for a threading-ab initio
model were the crystal structure of chondroitin polymerase
from E. coli (PDB code 2Z8675), the structure of the human
UDP-GalNAc:polypeptide α-N-acetylgalactosaminyltransfer-
ase-T2 (PDB codes 2FFU,76 5AJO77 and 4D0T78), and the
crystal structure of the human pp-GalNAc-T10 (pdb code
2D7I74). Notably, the PDB entry 4D0T was also used as a
template for LARGE1 domain 2 model building in the work
published by Bhattacharya.39 Sequence identities between
identified templates and LARGE1 domain 2 fall in the range
17−21% (see Supporting Information, Table S2, for details).
The top scoring model of domain 2 produced by I-TASSER
had a C-score value equal to −0.82, an estimated TM-score of
0.61 ± 0.14 Å and an estimated rmsd of 7.8 ± 4.4 Å. The
closest structural analogue to the model of domain 2, found by
I-TASSER in the Protein Data Bank is 2FFU, with a TM-score
of 0.87 (rmsd 1.61 Å), where a TM-score higher than 0.5
generally indicates the same fold in SCOP/CATH. In
agreement with the study of Bhattacharya and colleagues,39
the crystal structure with PDB code 4D0T, that is, the human
glycosyltransferase GalNAc-T2 in complex with UDP-GalNAc,
the EA2 peptide, and manganese ion, was also found to have a
close structural similarity to the model of LARGE1 domain 2
(TM-score of 0.84 and rmsd of 1.66 Å). The analysis of the
stereochemical quality of this model, assessed with PRO-
CHECK, showed that 95.5%, 1.6, and 2.8% of the residues are
located within the core and allowed, generously allowed, and
disallowed regions of the Ramachandran plot, respectively. The
overall model quality shows a ProSA-web Z-score of −7.2, in
agreement with the Z-scores calculated for the experimentally
resolved structures in the Protein Data Bank (Supporting
Information Figure S5A). The ProSA-web server showed that
the interaction energy of each residue with the rest of the
protein has negative values, apart from the residues within the
two small regions 584−590 and 597−601 (Supporting
Information, Figure S5B). Comparison of the results obtained
using the two modelling approaches led to the selection of the
structural model built with I-TASSER as the best model of
LARGE1 domain 2 (Figure 5).
Although the I-TASSER server performed better than
HHpred in terms of quality of the final model, the results
from both methods agree on pointing toward domain 2 to be
classified as an enzyme of the GT-A family, with a Rossman-
like fold consisting of a two sandwiched β-sheets interposed
between four α-helices on both sides (Figure 5A). Interest-
ingly, although the fold, especially the arrangement of the β-
sheets, is conserved between the two domains of LARGE1, the
three-dimensional model of domain 2 shows a lower number
of strands with respect to domain 1 (eight vs nine) (Figures 3A
and 5A). Strand β8 undergoes a distortion at the level of
Pro699 that makes its C-terminal portion parallel to the β6
strand and its N-terminal portion antiparallel to the β5 strand,
thus creating the double β-sheet structure shown in Figure 5B.
Interestingly, the third DXD motif, that in domain 2 is DID
(563−565), essential for the glucuronyltransferase activity of
LARGE1,18,22 is located in a small unstructured turn between
the strands β4 and β5, and it is structurally aligned with the
DXH motif of the structural neighbor UDP-GalNAc:polypep-
tide α-N-acetylgalactosaminyltransferase-T2 from H. sapiens.
The turn region is located deep into the binding cleft of the
enzyme, with the two aspartates (Asp563 and Asp565)
pointing toward the solvent and the isoleucine (Ile564) buried
in the protein core, indicating an orientation that could favor
the coordination of the carboxyl groups of the aspartates to a
metal ion cofactor such as Mn2+79 (Figure 5B). It is
noteworthy that His705, in the β8 strand, is conserved in
2FFU (His359, see sequence alignment in Figure 6) and that
in the crystal structure, this residue coordinates the metal ion.
His705 in the model of domain 2 is in close contact with the
aspartates 563 and 565 (distance shorter than 4 Å), suggesting
an involvement of this basic residue in the catalytic cluster
(Figure 5B).
Effects of the S331F Mutation on the Structure and
Dynamics of LARGE1 Domain 1. The mutation of the
LARGE1 residue Ser331 to Phe has been known for some time
to cause a congenital muscular dystrophy phenotype
characterized by eye malformations and mental retardation.26
According to our in silico generated structure of domain 1,
Ser331 is located in a random coil region (residues 325−333)
between helices I and J, on the rim of the active-site cleft and
close to Asn213, which belongs to the coil region between
strand β3 and helix C (residues 200−219) (Figure 3B).
Molecular dynamics simulations of the WT and of the S331F
mutant were carried out to explore the conformational changes
that occur upon S331F replacement and to assess its structural
and dynamics effects on the enzyme function, with the final
aim of understanding the molecular mechanism at the basis of
Figure 5. Structure and topology of LARGE1 domain 2. (A)
Topology diagram of the domains. Helices are shown as red spheres,
and β-strands are shown as yellow triangles. (B) Structural model is
represented as a cartoon, and the secondary structure is colored
(helices in red, β-strands in green, and random coils in magenta).
Individual side chains are represented as green balls and sticks.
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the pathological alterations induced by this mutation. Two
different MD replicates were performed for both WT and
S331F mutant. The stability of the two systems has been
evaluated by measuring the rmsd of the alpha carbons with
respect to their positions at time 0, over the simulation time.
After an equilibration of 40 ns, the rmsd reached a plateau with
a stable value of 4.4 ± 0.2 and of 4.5 ± 0.2 Å for WT and
S311F, respectively (Figure 7A), until the end of the
simulations. An analysis of the Cα atom root mean square
fluctuation (RMSF) with respect to their average positions
calculated over the last 200 ns was then performed, in order to
identify the regions of the protein whose movements are
mostly affected by the replacement of Ser311 with a Phe
residue (Figure 7B). The results indicate that most of the
residues share similar fluctuations. The differences in RMSF
between the two simulated systems are shown in Figure 7C,
which reveals larger fluctuations from the averaged MD
conformations in the unstructured regions spanning residues
178−180, 290−292, 324, 367−368, and 410−413.
Although several residues were found to display significant
differences in RMSF upon mutation, the important catalytic
residues such as the two DXD motifs and His380 were not
affected in their atomic fluctuations. An alteration of total,
hydrophobic, and hydrophilic SASAs in the mutant protein
with respect to the WT was also observed. A representative
plot of SASA for all-atom, hydrophobic, and polar residues
against time is shown in Figure 8.
Compared to the WT, the S331F mutant showed higher all-
atom SASAs, which converged to an average value of 15145 ±
248 Å2 (14777 ± 327 Å2 in the WT protein). Notably, the
hydrophobic SASA of the mutant increased about 12.7% over
the simulation time with respect to the WT protein (5115 ±
265 and 4538 ± 166 Å2, respectively) (Figure 8), a feature that
could significantly affect the interactions at the protein surface.
In order to check the convergence of the MD simulations,
we have performed the RMSIP analysis on two equilibrated
Figure 6. Structure-based sequence alignment of LARGE1 domain 2 and UDP-GalNAc:Polypeptide α-N-acetylgalactosaminyltransferase-2. The
figure was prepared using the ESPript server (http://espript.ibcp.fr). Identical residues are shown in white on red, and homologous residues are in
red letters. Secondary structure details are represented (helices: squiggles, beta strands: arrows, and turns: TT letters).
Figure 7. Analysis of MD trajectories. (A) Cα-rmsd from the starting
structure. (B) Residue-based Cα-RMSF relative to the average
structure. (C) ΔRMSF: difference between the RMSF of the mutant
S331F and that of the WT for each residue. A positive value indicates
larger fluctuations for the mutant, whereas a negative value means
larger fluctuations for the WT. Plots relative to the WT system are
colored in blue and those relative to the S331F mutant in orange.
Journal of Chemical Information and Modeling pubs.acs.org/jcim Article
https://dx.doi.org/10.1021/acs.jcim.0c00281
J. Chem. Inf. Model. 2020, 60, 3145−3156
3151
regions of the trajectories. The obtained high RMSIP values of
0.80 (replica#1), 0.82 (replica#2) and 0.82 (replica#1), 0.83
(replica#2) for the WT and mutant proteins, respectively, are
indicative of an adequate level of convergence.
The local conformational changes that occur upon S331F
mutation have been inspected by analyzing the non-bonding
interactions established by Ser/Phe331. In the WT simu-
lations, Ser331 is hydrogen bonded, by means of its OG and O
backbone oxygen atoms, to Asn213 (O backbone oxygen, ND2
and OD1 atoms), whereas in the mutant, Phe331 moves away
from Asn213, thus causing a conformational change in loops
200−219 and 325−333 (Figures 9 and 10). All plots of the
duplicate trajectories were similar and are shown in the
Supporting Information (Figures S6−S8).
A weak destabilizing effect of the S331F mutation (ΔΔG =
0.21 kcal/mol) was also calculated by FoldX. This ΔΔG value,
which cannot be directly related to a change in enzyme
function,80 suggests that a phenylalanine in position 331 is not
fully compatible with the surrounding chemical environment,
as already observed in MD. Time evolution of the secondary
structure elements along the MD simulation was also analyzed,
showing the stability of the β-strand elements during the entire
MD simulations and the structural transition of few α-helices
into 310-helices (Supporting Information, Figure S9).
In order to probe the changes in conformational dynamics
induced by the S331F mutation, analysis of the MD trajectory
by PCA using the Ca atoms was also performed. Results
indicate that the first twenty principal components (PCs)
account for 90.7% (WT) and 92.8% (mutant) of the motions
observed in the last 400 ns of the trajectories, whereas the first
three PCs account for the 74.5% (WT) and the 82.3%
(mutant) motions (Supporting Information, Figure S10A).
The trace values of the diagonalized covariance matrix were
found to be 1706.9 Å2 (WT) and 2145.8 Å2 (mutant),
indicating an increased flexibility of S331F in the collective
motion as compared to the WT (Supporting Information,
Figure S10A,B). Analysis of the contribution of each residue to
the first principal component revealed that the Ser 331 to Phe
mutation alters the protein motion in the loop regions
surrounding the residue 331. Notably, the peaks corresponding
to residues 211−216 and 282−291 are shifted backward (to
201−210 and 276−288, respectively) in the mutated protein
(Supporting Information, Figure S10C). This analysis suggests
that the S331F mutation introduces local differences in the
motion of the active site rim of domain 1, which might affect
the interaction with the substrate.
Cloning and Expression of LARGE1 Domain 1 in E.
coli. A series of first attempts at heterologous expression of
domain 1 as revealed by our modelling results were carried out.
The DNA sequence coding for the region comprising residues
138−413 ofM. musculus LARGE1 was custom-synthesized and
optimized for the expression in E. coli. The synthetic gene thus
Figure 8. Analysis of MD trajectories. Time series of the SASA of LARGE1 domain 1. The evolution of the total, hydrophobic, and hydrophilic
SASA over the simulation time is shown in panels (A−C), respectively. (D) Percentage of hydrophobic SASA (hyd-SASA) and hydrophilic SASA
(phil-SASA) with respect to the total SASA. Each time-series refers to both the simulation replicas. For color code, see Figure 7.
Figure 9. Representative structures of the simulated LARGE1 WT
and S331F mutant. The structurally closest frame to the averaged
structure from the MD simulations (obtained selecting the frame with
the lowest Cα-rmsd with respect to the average Cα-coordinates
calculated over the equilibrated trajectory) is reported for each
simulated system. Panel (A) shows the average structures from the
WT simulation, and panel (B) shows the average structures from the
S331F mutant simulation. The backbone is represented as tube
colored in grey, the atomic details are represented as sticks colored by
atom type, and the black dashed line represents the hydrogen bond
interaction.
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obtained was cloned into the pHisTrx vector for expression
downstream the fusion partner His6-tagged thioredoxin and
subsequently transformed into E. coli strain BL21 (DE3).
Although preliminary, the evidence that the protein can be
recovered in the soluble form upon heterologous expression in
the presence of helper proteins such as the chaperonin GroEL
(see Supporting Information, Figures S11−S13) reinforce the
notion that the subdomain 1 represents an autonomous folding
unit, as suggested by our modelling results.
Further experiments are granted aimed at producing
quantitative amounts of domain 1 for future biochemical and
structural studies. Recombinant expression of individual
LARGE1 domains 1 and 2, as well of the two domains
together in a full-length LARGE1 construct, would allow a
thorough analysis of the enzymatic proprieties and activity of
this glycosyltransferase. The two catalytic domains of LARGE1
are connected by a flexible linker (ranging from amino acid
414 to 472) that due to its nature could not be accurately
modeled. A very interesting question is whether the two
domains establish long-range interactions and work somehow
cooperatively during the sequential synthesis of each added
disaccharide block (i.e. the final product of every full LARGE1
enzymatic cycle) or rather function in an independent fashion.
Whether the binding of each substrate to each catalytic domain
induces any allosteric long-range effects influencing the
enzymatic behavior of the other catalytic domain remains to
be determined at the current stage. Noteworthy, also the N-
terminal region of α-dystroglycan81 harbors two different
domains (IG1 and S6), and it is intriguing to foresee a scenario
in which the two DG domains would be involved reciprocally
in chaperoning the activity of the two catalytic domains of
LARGE1.
■ CONCLUSIONS
Our combined use of molecular modelling approaches allowed
for a three-dimensional description of the two domains
respectively responsible for the xylosyltransferase and glucur-
onyltransferase activities of LARGE1. This work characterized
the three DXD motifs, each likely to bind a manganese cation
(Mn2+), that constitute the active sites for the glycosyltransfer-
ase activities of the two domains,22,69,82 thus offering some
initial insight into the possible mechanism of binding of the
sugar donor and acceptor. Molecular dynamic simulations of
the S331F mutant, carried out in comparison with the WT
counterpart, points to a more flexible and less stable enzyme, as
suggested by an increased RMSF and all-atom and hydro-
phobic SASA parameters, compared to the WT protein.
Indeed, a reduced stability could be at the basis of the poorer
enzymatic activity of this variant of LARGE. This would
eventually lead to the hypoglycosylation of α-DG observed in a
patient affected by a severe form of congenital muscular
dystrophy with anomalies of eye and brain linked to this
missense mutation.26
Our study demonstrates that in the absence of experimental
structural data on LARGE1, template-based three-dimensional
modelling of the enzyme can offer some insight into its overall
structural features, and the analysis of its dynamic behavior by
in silico methods can help to elucidate the molecular
mechanism underneath the diseases linked to missense
mutations of the enzyme. In addition, our modelling study
might pave the road for the analysis of potential complexes
formed by LARGE1 and the α-dystroglycan N-terminal
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Sequence alignment of human and murine LARGE1
proteins; structural analysis of the LARGE1 domain 1
model structure generated by the I-TASSER server;
sequence identity between LARGE domain 1 and the
templates used by I-TASSER to build the model;
structural analysis of the LARGE1 domain 2 model
generated by HHPRED/MODELLER approach; struc-
tural analysis of the LARGE1 domain 2 model generated
by the I-TASSER server; analysis of MD trajectories;
time evolution of the secondary structural elements
along the MD simulations generated by VMD [78];
projection of the enzyme conformations onto the first
two PCs for the wild-type (in blue) and mutant (in
Figure 10. Analysis of MD trajectories. Frequency of the hydrogen
bonds (%) between Ser331 and Asn213 in domain 1 WT (A) and
S331F (B). Time evolution of the distances between the geometric
centroids of the Phe331 and Asn213 side chain atoms (C) and
between the O backbone atoms of Phe331 and Asn213 (black and
grey, respectively).
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Hara, Y.; Beltrań Valero de Bernabe,́ D.; Yu, L.; Wright, K. M.;
Campbell, K. P. The glucuronyltransferase B4GAT1 is required for
initiation of LARGE-mediated α-dystroglycan functional glycosyla-
tion. eLife 2014, 3, No. e03941.
(62) Cuff, M. E.; Tesar, C.; Bearden, J.; Joachimiak, A. The Structure
of a Protein in Glycosyl Transferase Family 8 from Anaerococcus Prevotii,
2011.
(63) Persson, K.; Ly, H. D.; Dieckelmann, M.; Wakarchuk, W. W.;
Withers, S. G.; Strynadka, N. C. J. Crystal structure of the retaining
galactosyltransferase LgtC from Neisseria meningitidis in complex
with donor and acceptor sugar analogs. Nat. Struct. Biol. 2001, 8,
166−175.
(64) Yu, H.; Takeuchi, M.; LeBarron, J.; Kantharia, J.; London, E.;
Bakker, H.; Haltiwanger, R. S.; Li, H.; Takeuchi, H. Notch-modifying
xylosyltransferase structures support an SNi-like retaining mechanism.
Nat. Chem. Biol. 2015, 11, 847−854.
(65) Lairson, L. L.; Chiu, C. P. C.; Ly, H. D.; He, S.; Wakarchuk, W.
W.; Strynadka, N. C. J.; Withers, S. G. Intermediate trapping on a
mutant retaining α-galactosyltransferase identifies an unexpected
aspartate residue. J. Biol. Chem. 2004, 279, 28339−28344.
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